litlas
Log inCreate account

Talia Golan

Active 1997–2025

87
Papers
18,924
Citations
50
h-index
85
i10-index

Citations

Citations per year for Talia Golan1979: 1 citations1996: 1 citations2000: 1 citations2001: 1 citations2002: 2 citations2003: 2 citations2004: 3 citations2005: 1 citations2006: 2 citations2007: 2 citations2008: 1 citations2009: 3 citations2010: 1 citations2011: 3 citations2012: 6 citations2013: 5 citations2014: 8 citations2015: 30 citations2016: 32 citations2017: 101 citations2018: 188 citations2019: 589 citations2020: 996 citations2021: 1,378 citations2022: 1,232 citations2023: 1,006 citations2024: 1,584 citations2025: 1,005 citations2026: 49 citations1980–1995: no citations, so these years are not shown1997–1999: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,439 citing papers, 23.2% of this breakdownChina: 2,178 citing papers, 20.7% of this breakdownItaly: 544 citing papers, 5.2% of this breakdownGermany: 499 citing papers, 4.8% of this breakdownUnited Kingdom: 483 citing papers, 4.6% of this breakdownFrance: 366 citing papers, 3.5% of this breakdownJapan: 352 citing papers, 3.4% of this breakdownCanada: 287 citing papers, 2.7% of this breakdownSpain: 286 citing papers, 2.7% of this breakdownSouth Korea: 266 citing papers, 2.5% of this breakdownNetherlands: 219 citing papers, 2.1% of this breakdownIsrael: 210 citing papers, 2% of this breakdown
0%23.2%Other 22.6%

Institutions

Fields

  • Medicine55.3%
  • Biochemistry, Genetics and Molecular Biology32.7%
  • Immunology and Microbiology7.1%
  • Engineering1.6%
  • Computer Science0.8%
  • Materials Science0.5%
  • Other2%

Topics

  • Cancer Immunotherapy and Biomarkers8.6%
  • Pancreatic and Hepatic Oncology Research7.4%
  • Gut microbiota and health4.7%
  • Cancer Genomics and Diagnostics4.7%
  • Gastric Cancer Management and Outcomes2.5%
  • Cancer Research and Treatments2.4%
  • Other69.7%

Coauthors

All papers

Open in search
  1. The human tumor microbiome is composed of tumor type–specific intracellular bacteria

    Authors: Deborah Nejman, Ilana Livyatan, Garold Fuks, Nancy Gavert, Yaara Zwang, Leore T. Geller, Aviva Rotter-Maskowitz, Roi Weiser, Giuseppe Mallel, Elinor Gigi, Arnon Meltser, Gavin M. Douglas, Iris Kamer, Vancheswaran Gopalakrishnan, Tali Dadosh, Smadar Levin‐Zaidman, Sofia Avnet, Tehila Atlan, Zachary A. Cooper, Reetakshi Arora, Alexandria P. Cogdill, Md Abdul Wadud Khan, Gabriel O Ologun, Yuval Bussi, Adina Weinberger, Maya Lotan‐Pompan, Ofra Golani, Gili Perry, Merav Rokah, Keren Bahar‐Shany, Elisa A. Rozeman, Christian U. Blank, Anat Ronai, Ron Shaoul, Amnon Amit, Tatiana Dorfman, Ran Kremer, Zvi R. Cohen, Sagi Harnof, Tali Siegal, Einav Yehuda‐Shnaidman, Einav Nili Gal‐Yam, Hagit Shapira, Nicola Baldini, Morgan G. I. Langille, Alon Ben‐Nun, Bella Kaufman, Aviram Nissan, Talia Golan, Maya Dadiani, Keren Levanon, Jair Bar, Shlomit Yust‐Katz, Iris Barshack, Daniel S. Peeper, Dan J. Raz, Eran Segal, Jennifer A. Wargo, Judith Sandbank, Noam Shental, Ravid Straussman - Science 2020 cited by 2,471

  2. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine

    Authors: Leore T. Geller, Michal Barzily-Rokni, Tal Danino, Oliver Jonas, Noam Shental, Deborah Nejman, Nancy Gavert, Yaara Zwang, Zachary A. Cooper, Kevin Shee, Christoph A. Thaiss, Alexandre Reuben, Jonathan Livny, Roi Avraham, Dennie T. Frederick, Matteo Ligorio, Kelly Chatman, Stephen Johnston, Carrie M. Mosher, Alexander Brandis, Garold Fuks, Candice R. Gurbatri, Vancheswaran Gopalakrishnan, Michael P. Kim, Mark W. Hurd, Matthew H. G. Katz, Jason B. Fleming, Anirban Maitra, David A. Smith, Matt Skalak, Jeffrey Bu, Monia Michaud, Sunia A. Trauger, Iris Barshack, Talia Golan, Judith Sandbank, Keith T. Flaherty, Anna Mandinova, Wendy S. Garrett, Sarah P. Thayer, Cristina R. Ferrone, Curtis Huttenhower, Sangeeta N. Bhatia, Dirk Gevers, Jennifer A. Wargo, Todd R. Golub, Ravid Straussman - Science 2017 cited by 1,812

  3. Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer

    Authors: Talia Golan, Pascal Hammel, Michele Reni, Eric Van Cutsem, Teresa Macarulla, Michael J. Hall, Joon-Oh Park, Daniel Hochhauser, Dirk Arnold, Do‐Youn Oh, Anke Reinacher‐Schick, Giampaolo Tortora, Hana Algül, Eileen M. O’Reilly, David McGuinness, Karen Cui, Katia Schlienger, Gershon Y. Locker, Hedy L. Kindler - New England Journal of Medicine 2019 cited by 2,213

  4. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer

    Authors: Charles S. Fuchs, Toshihiko Doi, Raymond Woo-Jun Jang, Kei Muro, Taroh Satoh, Manuela Machado, Weijing Sun, Shadia I. Jalal, Manish A. Shah, Jean-Phillipe Metges, Marcelo Garrido, Talia Golan, Mario Mandalà, Zev A. Wainberg, Daniel V.T. Catenacci, Atsushi Ohtsu, Kohei Shitara, Ravit Geva, Jonathan Bleeker, Andrew H. Ko, Geoffrey Y. Ku, Philip Philip, Peter C. Enzinger, Yung‐Jue Bang, Diane Levitan, Jiangdian Wang, Minori Koshiji Rosales, Rita P. Dalal, Harry H. Yoon - JAMA Oncology 2018 cited by 1,812

  5. Hallmarks of transcriptional intratumour heterogeneity across a thousand tumours

    Authors: Avishai Gavish, Michael Tyler, Alissa Greenwald, Rouven Hoefflin, Dor Simkin, Roi Tschernichovsky, Noam Galili Darnell, Einav Somech, Chaya Barbolin, Tomer Antman, Daniel Kovarsky, Thomas F. Barrett, L. Nicolas Gonzalez Castro, Debdatta Halder, Rony Chanoch-Myers, Julie Laffy, Michael Mints, Adi Wider, Rotem Tal, Avishay Spitzer, Toshiro Hara, Maria Raitses‐Gurevich, Chani Stossel, Talia Golan, Amit Tirosh, Mario L. Suvà, Sidharth V. Puram, Itay Tirosh - Nature 2023 cited by 538

  6. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

    Authors: Thierry Conroy, Per Pfeiffer, Valérie Vilgrain, Ángela Lamarca, Thomas Seufferlein, Eileen M. O’Reilly, Thilo Hackert, Talia Golan, Gerald W. Prager, Karin Haustermans, Arndt Vogel, Michel Ducreux - Annals of Oncology 2023 cited by 511

  7. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

    Authors: Bruno Bockorny, Valerya Semenisty, Teresa Macarulla, Erkut Borazanci, Brian M. Wolpin, Salomon M. Stemmer, Talia Golan, Ravit Geva, Mitesh J. Borad, Katrina S. Pedersen, Joon Oh Park, Robert A. Ramirez, David Gutiérrez Abad, Jaime Feliú, Andrés Muñoz, Mariano Ponz‐Sarvisé, Amnon Peled, Tzipora M Lustig, Osnat Bohana‐Kashtan, Stephen M. Shaw, Ella Sorani, Marya Chaney, Shaul Kadosh, Abi Vainstein Haras, Daniel D. Von Hoff, Manuel Hidalgo - Nature Medicine 2020 cited by 533

  8. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆

    Authors: Jiaxin Niu, Corinne Maurice‐Dror, D.H. Lee, D.-W. Kim, Adnan Nagrial, Mark Voskoboynik, Hyun Cheol Chung, Kathryn F. Mileham, Ulka N. Vaishampayan, Drew Rasco, Talia Golan, Todd M. Bauer, Antonio Jimeno, Vincent Chung, Elliot Chartash, Mallika Lala, Q. Chen, Jane Healy, Myung‐Ju Ahn - Annals of Oncology 2021 cited by 287

  9. Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas

    Authors: Kevin J. Harrington, Joshua Brody, M. Ingham, James Strauss, Sašo Čemerski, M. Wang, Archie Tse, Anuradha Khilnani, Aurélien Marabelle, Talia Golan - Annals of Oncology 2018 cited by 276

  10. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

    Authors: Kei Muro, Hyun Cheol Chung, Veena Shankaran, Ravit Geva, Daniel V.T. Catenacci, Shilpa Gupta, Joseph P. Eder, Talia Golan, Dung T. Le, Barbara Burtness, Autumn J. McRee, Chia‐Chi Lin, Kumudu Pathiraja, Jared Lunceford, Kenneth Emancipator, Jonathan Juco, Minori Koshiji, Yung‐Jue Bang - The Lancet Oncology 2016 cited by 1,131

  11. A deep-learning framework to predict cancer treatment response from histopathology images through imputed transcriptomics

    Authors: Danh-Tai Hoang, Gal Dinstag, Eldad D. Shulman, Leandro C. Hermida, Doreen S. Ben-Zvi, Efrat Elis, Katherine Caley, Stephen‐John Sammut, Sanju Sinha, Neelam Sinha, Christopher H. Dampier, Chani Stossel, Tejas Patil, Arun Rajan, Wiem Lassoued, Julius Strauss, Shania Bailey, Clint Allen, Jason M. Redman, Tuvik Beker, Peng Jiang, Talia Golan, Scott Wilkinson, Adam G. Sowalsky, Sharon R. Pine, Carlos Caldas, James L. Gulley, Kenneth Aldape, Ranit Aharonov, Eric A. Stone, Eytan Ruppin - Nature Cancer 2024 cited by 133

  12. Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer

    Authors: Hedy L. Kindler, Pascal Hammel, Michele Reni, Eric Van Cutsem, Teresa Macarulla, Michael J. Hall, Joon Oh Park, Daniel Hochhauser, Dirk Arnold, Do‐Youn Oh, Anke Reinacher‐Schick, Giampaolo Tortora, Hana Algül, Eileen M. O’Reilly, Sonal Bordia, David McGuinness, Karen Cui, Gershon Y. Locker, Talia Golan - Journal of Clinical Oncology 2022 cited by 225

  13. Identification of tissue-specific cell death using methylation patterns of circulating DNA

    Authors: Roni Lehmann‐Werman, Daniel Neiman, Hai Zemmour, Joshua Moss, Judith Magenheim, Adi Vaknin‐Dembinsky, Sten Rubertsson, Bengt Nellgård, Kaj Blennow, Henrik Zetterberg, Kirsty L. Spalding, Michael J. Haller, Clive Wasserfall, Desmond Schatz, Carla J. Greenbaum, Craig Dorrell, Markus Grompe, Aviad Zick, Ayala Hubert, Myriam Maoz, Volker Fendrich, Detlef K. Bartsch, Talia Golan, Shmuel A. Ben Sasson, Gideon Zamir, Aharon Razin, Howard Cedar, A. M. James Shapiro, Benjamin Gläser, Ruth Shemer, Yuval Dor - National Academy of Sciences, Proceedings of the National Academy of Sciences 2016 cited by 621

  14. RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients

    Authors: Talia Golan, Elina Zorde Khvalevsky, Ayala Hubert, Rachel Malka Gabai, Naama Hen, Amiel Segal, Abraham J. Domb, Gil Harari, Eliel Ben-David, Stephen Raskin, Yuri Goldes, Eran Goldin, Rami Eliakim, Maor Lahav, Yael Kopleman, Alain Dancour, Amotz Shemi, Eithan Galun - Oncotarget 2015 cited by 326

  15. Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers

    Authors: Aatur D. Singhi, Ben George, Joel Greenbowe, Jon Chung, James Suh, Anirban Maitra, Samuel J. Klempner, Andrew Hendifar, Javle Milind, Talia Golan, Randall E. Brand, Amer H. Zureikat, Somak Roy, Alexa B. Schrock, Vincent A. Miller, Jeffrey S. Ross, Siraj M. Ali, Nathan Bahary - Gastroenterology 2019 cited by 337

  16. A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer

    Authors: Elena Garralda, Ammar Sukari, Nehal J. Lakhani, Akash Patnaik, Yiyun Lou, Seock‐Ah Im, Talia Golan, Ravit Geva, Martin Wermke, M. de Miguel, J. Palcza, S. Jha, Marya Chaney, Anson K. Abraham, Jasmine Healy, Gerald S. Falchook - ESMO Open 2022 cited by 88

  17. RBFOX2 modulates a metastatic signature of alternative splicing in pancreatic cancer

    Authors: Amina Jbara, Kuan‐Ting Lin, Chani Stossel, Zahava Siegfried, Haya Shqerat, Adi Amar-Schwartz, Ela Elyada, Maxim Mogilevsky, Maria Raitses‐Gurevich, Jared L. Johnson, Tomer M. Yaron, Ofek Ovadia, Gun Ho Jang, Miri Danan-Gotthold, Lewis C. Cantley, Erez Y. Levanon, Steven Gallinger, Adrian R. Krainer, Talia Golan, Rotem Karni - Nature 2023 cited by 90

  18. Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation

    Authors: Eileen M. O’Reilly, Jonathan W. Lee, Mark M. Zalupski, Marinela Capanu, Jennifer Park, Talia Golan, Esther Tahover, Maeve A. Lowery, Joanne F. Chou, Vaibhav Sahai, Robin Brenner, Hedy L. Kindler, Kenneth H. Yu, Alice Zervoudakis, Shreya Vemuri, Zsofia K. Stadler, Richard Kinh Gian, Neesha C. Dhani, Alice P. Chen, David P. Kelsen - Journal of Clinical Oncology 2020 cited by 398

  19. Integration of Genomic and Transcriptional Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases

    Authors: Ashton A. Connor, Robert E. Denroche, Gun Ho Jang, Mathieu Lemire, Amy Zhang, Michelle Chan‐Seng‐Yue, Gavin W. Wilson, Robert C. Grant, Daniele Merico, Ilinca M. Lungu, John M.S. Bartlett, Dianne Chadwick, Sheng-Ben Liang, Jenna Eagles, Faridah Mbabaali, Jessica K. Miller, Paul M. Krzyzanowski, Heather Armstrong, Xuemei Luo, Lars Jorgensen, Joan Miguel Romero, Prashant Bavi, Sandra E. Fischer, Stefano Serra, Sara Hafezi‐Bakhtiari, Derin Çağlar, Michael H. A. Roehrl, Sean P. Cleary, Michael A. Hollingsworth, Gloria M. Petersen, Sarah P. Thayer, Calvin Law, Sulaiman Nanji, Talia Golan, Alyssa Smith, Ayelet Borgida, Anna Dodd, David W. Hedley, Bradly G. Wouters, Grainne M. O’Kane, Julie M. Wilson, George Zogopoulos, Faiyaz Notta, Jennifer J. Knox, Steven Gallinger - Cancer Cell 2019 cited by 247

  20. ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility: summary and recommendations

    Authors: Mandeep Sawhney, Audrey H. Calderwood, Nirav Thosani, Timothy R. Rebbeck, Sachin Wani, Marcia Irene Canto, Douglas S. Fishman, Talia Golan, Manuel Hidalgo, Richard S. Kwon, Douglas L. Riegert‐Johnson, Dushyant V. Sahani, Elena M. Stoffel, Charles M. Vollmer, Bashar Qumseya - Gastrointestinal Endoscopy 2022 cited by 134

  21. Senescent cancer-associated fibroblasts in pancreatic adenocarcinoma restrict CD8+ T cell activation and limit responsiveness to immunotherapy in mice

    Authors: Benjamin Assouline, Rachel E. Kahn, Lutfi Hodali, Reba Condiotti, Yarden Engel, Ela Elyada, Tzlil Mordechai-Heyn, Jason R. Pitarresi, Dikla Atias, Eliana Steinberg, Tirza Bidany-Mizrahi, Esther Forkosh, Lior H. Katz, Ofra Benny, Talia Golan, Matan Hofree, Sheila A. Stewart, Karine Atlan, Gideon Zamir, Ben Z. Stanger, Michael Berger, Ittai Ben‐Porath - Nature Communications 2024 cited by 78

  22. BRCA mutational status shapes the stromal microenvironment of pancreatic cancer linking clusterin expression in cancer associated fibroblasts with HSF1 signaling

    Authors: Lee Shaashua, Aviad Ben‐Shmuel, Meirav Pevsner‐Fischer, Gil Friedman, Oshrat Levi-Galibov, Subhiksha Nandakumar, Debra Barki, Reinat Nevo, Lauren E. Brown, Wenhan Zhang, Yaniv Stein, Chen Lior, Han Sang Kim, Linda Bojmar, William R. Jarnagin, Nicolas Lecomte, Shimrit Mayer, Roni Stok, Hend Bishara, Rawand Hamodi, Ephrat Levy‐Lahad, Talia Golan, John A. Porco, Christine A. Iacobuzio–Donahue, Nikolaus Schultz, David A. Tuveson, David Lyden, David P. Kelsen, Ruth Scherz‐Shouval - Nature Communications 2022 cited by 82

  23. Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma

    Authors: Talia Golan, Grainne M. O’Kane, Robert E. Denroche, Maria Raitses‐Gurevich, Robert C. Grant, Spring Holter, Yifan Wang, Amy Zhang, Gun Ho Jang, Chani Stossel, Dikla Atias, Sharon Halperin, Raanan Berger, Yulia Glick, J. Patrick Park, Adeline Cuggia, Laura Williamson, Hui‐Li Wong, David F. Schaeffer, Daniel J. Renouf, Ayelet Borgida, Anna Dodd, Julie M. Wilson, Sandra E. Fischer, Faiyaz Notta, Jennifer J. Knox, George Zogopoulos, Steven Gallinger - Gastroenterology 2021 cited by 152

  24. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers

    Authors: Talia Golan, Zaheer Kanji, Ron Epelbaum, Nicholas Devaud, Efrat Dagan, Spring Holter, Dan Aderka, Shani Paluch–Shimon, Brett A. Kaufman, Ruth Gershoni‐Baruch, David W. Hedley, Malcolm J. Moore, Eitan Friedman, Steven Gallinger - British Journal of Cancer 2014 cited by 438